

## **CUMULATIVE INDEX**

### **Volume 26, Numbers 1-4, 1983**

Abdominal injuries in pregnancy, 906-907  
  penetrating, 903-904, 910

Abortion  
  incomplete, contact hysteroscopy in, 237-238  
  induced  
    contact hysteroscopy in, 239  
    in lupus erythematosus, 549-550

inevitable, cervical changes in, 13

spontaneous  
  and alcohol use, 440  
  in anesthetic-exposed women, 450-451  
  contact hysteroscopy in, 238-239  
  immune system in, 532  
  in lupus erythematosus, 550-551  
  in myasthenia gravis, 596  
  and smoking, 443

Abruptio placentae, in traumatic injuries, 907-908

Acetaminophen in pregnancy, in autoimmune diseases, 637

Actin filaments, in uterine contractile activity, 58, 78

Actinomycin D, 393-394

Adenoma of breast, in pregnancy, 858-860

Adenosis, vaginal, and postmenopausal bleeding, 775

Adhesions, intrauterine  
  hysteroscopy in, 270, 303-308  
  microhysteroscopy in, 294

Adolescence, menstrual disorders in, 690-700

Adrenal gland  
  congenital hyperplasia of, menarchal delay in, 693  
  disorders with amenorrhea, 754-755  
  disorders in pregnancy, 882-884  
    pheochromocytoma, 876-882

Adrenalectomy, pregnancy after, 884

Aging, and menstruation changes, 762

Alcohol  
  in breast milk, 465  
  as hazard to reproduction, 433  
  in inhibition of labor, 64  
  intake in pregnancy, 437-442  
    animal studies of, 440-441  
    and dose-effect relationship, 441-442  
    and fetal alcohol syndrome, 437-440  
    and outcome of pregnancy, 440

Aldosterone secretion in pregnancy, 892

Aldosteronism, in pregnancy, 883-884

Alexandria unit, for uterine activity, 83

Amebic abscess of liver, in pregnancy, 814-815

Amenorrhea, 749-757  
  in adolescence, 690-700  
  adrenal causes of, 754-755  
  differential diagnosis of, 749-755  
  evaluation of, 755-756  
  in exercise and sports, 732-733, 750, 751  
  in hyperprolactinemia, 740-741  
  hypothalamic causes of, 749-751  
  ovarian causes of, 753-754  
  pituitary causes of, 752-753  
  psychologic aspects of, 733, 751, 780  
  thyroid causes of, 755  
  treatment of, 756-757  
  uterine causes of, 754  
  in weight loss, 729, 732, 750

Amikacin, 393  
  in pregnancy, 398  
    toxicity of, 400

Amine odor of vaginal discharge, 190, 199

Aminoglycosides, 393  
  in pregnancy, 398-399

Aminopterin in pregnancy, affecting fetus, 433

Amniocentesis, in polyhydramnios, 415

Amnioscopy, contact hysteroscopy in, 239

Amniotic infection syndrome, in gonorrhea, 115

Amphotericin B, 393

Anemia, in rheumatoid arthritis, 566

Anesthesia  
  and agents as hazard to reproduction, 433  
  in hysteroscopy, 263  
    contact, 223  
    panoramic, 244-245  
  in laser vaporization of cervix, 985  
  in pregnancy, 795-800  
    in appendicitis, 807  
    and fetal outcome, 449-456  
    in myasthenia gravis, 597-598  
    teratogenicity of agents in, 797-798  
  in sterilization by laparoscopy, 322

Anorexia  
  in appendicitis, 803  
  nervosa, amenorrhea in, 751

Anovulation, in hyperprolactinemia, 741-742

## CUMULATIVE INDEX

Antibiotics in pregnancy, 391-405  
 aminoglycosides, 398-399  
 cephalosporins, 398  
 clindamycin, 399  
 erythromycin, 399  
 mechanism of action, 391-394  
 nitrofurantoin, 399  
 penicillins, 397-398  
 pharmacokinetics of, 394-401  
 sulfonamides, 399  
 toxicity and teratogenicity of, 399-401

Antibodies  
 to *Neisseria gonorrhoeae*, 118  
 to *Treponema pallidum*, 127

Anticholinesterase drugs, in myasthenia gravis, 598-600

Anticoagulants, in thromboembolic disease in pregnancy, 917-919

Anticonvulsants in pregnancy, affecting fetus, 427, 433

Appendectomy in pregnancy, 806-808  
 complications of, 807-808

Appendicitis in pregnancy, 801-809  
 differential diagnosis of, 805  
 errors in diagnosis of, 808  
 incidence of, 801  
 laboratory signs in, 804  
 maternal mortality in, 808  
 perforation in, 805  
 perinatal mortality in, 808-809  
 symptoms of, 801  
 treatment of, 806-808

Arrhythmias, fetal, treatment of, 415-416

Arthritis  
 gonococcal, 117  
 in lupus erythematosus, 548  
 rheumatoid, 558-575. *See also* Rheumatoid arthritis

Asherman's syndrome, 754  
 hysteroscopy in, 179-180  
 treatment of, 757

Aspirin in pregnancy  
 in autoimmune diseases, 635-637  
 in rheumatoid arthritis, 569-570

Autoimmune diseases in pregnancy, drug therapy in, 635-639

Automobile collisions, and injuries in pregnancy, 903

Azathioprine  
 in Crohn's disease, 829  
 in pregnancy  
 affecting fetus, 423  
 in autoimmune diseases, 639  
 in lupus erythematosus, 554  
 in rheumatoid arthritis, 572-573

Bacitracin, 393

Bacteruria in pregnancy, 401, 895-897

Bartholinitis, chlamydial, 147-148

Bendectin, teratogenic effects of, 424-425

Benzene, as hazard to reproduction, 427, 434

Benzodiazepines in pregnancy, affecting fetus, 426

Beta-receptor agonists, in inhibition of labor, 63-64

Biliary tract disease, in pregnancy, 810-818  
 gallbladder, 816-818  
 liver, 810-816

Bilirubin levels, in hyperemesis gravidarum, 813

Biopsy  
 cone, in cervical intraepithelial neoplasia, 968-978  
 complications of, 975-976  
 indications for, 968-970  
 pathology in, 974-975  
 in pregnancy, 976-977  
 in recurrent disease, 977-978  
 technique of, 970-974  
 fine-needle, in breast cancer, 861  
 of skin, fetal, 343

Bladder, endoscopy of, 347-358

Bleeding  
 from sterilization by laparoscopy, 330-331  
 uterine, abnormal. *See* Uterus, abnormal bleeding from

Blistering diseases, subepidermal, in pregnancy, 605-612

Blood constituents, in pregnancy, 796

Blood volume, in pregnancy, 522-523

Boric acid capsules, in candidiasis, 195

Bowel disorders. *See* Gastrointestinal tract

Breast disease in pregnancy, 853-863  
 adenomas, 858-860  
 cancer, 860-863  
 fibrocystic disease, 856-858  
 galactocele, 854  
 mastitis, 854-855

Breast milk, drugs and chemicals in, 396, 461-466

Bromocriptine  
 in hyperprolactinemia, 742; 745-746  
 in premenstrual syndrome, 713

Bubo, in chancroid, 139

Budd-Chiari syndrome, in pregnancy, 815

Burns  
 electrothermal, in sterilization by laparoscopy, 330  
 in pregnancy, 904, 911-912

Caffeine intake in pregnancy, affecting fetus, 425-426

Calcium  
 antagonists of  
 in inhibition of labor, 64-65  
 reducing uterine contractions, 68  
 and uterine contractile activity, 57-58, 78

Calculi, urinary, in pregnancy, 897-898

*Calymmatobacterium granulomatis*, 140

Candidiasis, vaginal, 195-197

Caplan's syndrome, 564

Carbon dioxide

## CUMULATIVE INDEX

Carbon dioxide (*continued*)  
 in laser endoscopy, 366-372  
 in microhysteroscopy, 286-288  
 in panoramic hysteroscopy, 242-251, 254, 262  
 Carbon disulfide, as hazard to reproduction, 433  
 Carcinogenesis, and prenatal exposure to radiation, 498-499  
 Carcinoma  
 of breast, in pregnancy, 860-863  
 of endometrium  
   hysteroscopy in, 228-230, 231-234, 249, 275  
   microhysteroscopy in, 292  
 of ovary, in pregnancy, 846-848  
 Cardiovascular system, in pregnancy, 795-796  
 Catecholestrogens, and gonadotropin secretion, 675-676  
 Cephalosporins, 393  
   in pregnancy, 398  
 Cervicitis  
   cervical discharge in, 190, 200  
   chlamydial, 148  
   gonococcal, 116  
 Cervicography, 1007-1015  
   borders with normal tissue in, 1012  
   color tone in, 1012  
   documentation with, 1014-1015  
   and evaluation of cervicograms, 1009  
   in follow-up examinations, 1014  
   intercapillary distance in, 1012  
   nomenclature for, 1009-1011  
   and prediction of histologic changes, 1011  
   prior to treatment of lesions, 1014  
   screening with, 1012-1013  
   surface pattern in, 1012  
   teaching of, 1015  
   technique of, 1008-1009  
 Cervimeter, measuring cervical dilatation in labor, 30-32  
 Cervix uteri  
   collagen in, 8, 18  
   in pregnancy, 10, 19-20, 38  
   dilatation in prostaglandin-induced labor, 88-89  
   elastin in, 9, 18  
   in pregnancy, 21  
   erosions in, and postmenopausal bleeding, 774  
   estrogens affecting, 23-24, 40-41, 60  
   fibromuscular junction of, 9  
   gross characteristics of, 8  
   incompetent os in, 33-34  
   in inevitable abortion, 13  
   intraepithelial neoplasia of, 925-1017  
     cervicography in, 1007-1015  
     cone biopsy in, 968-978  
     laser therapy in, 980-994  
     negative cytology in, 929-936  
     and papillomavirus infection, 949-964  
 Cervix uteri, intraepithelial neoplasia of (*continued*)  
   review questions, 1017  
   Semm cold coagulator in, 996-1005  
   vascular changes in, 938-948  
   in labor, 11, 20  
   mechanical properties of, 28-35  
     direct measurements of, 30-32  
     indirect measurements of, 32-35  
   microcolpohysteroscopy of, 290-291, 295-300  
   morphology of, 7  
   muscle of, 9-10  
   neoplasia of  
     contact hysteroscopy in, 225-227  
     microcolpohysteroscopy in, 298-300  
     polyps of, 771-773  
     in pregnancy, 10-11, 18-22  
     prelabor evaluation of, 38-39  
     priming of, 59-61  
       drug-induced, 39-44, 59-61  
       estrogens in, 40-41, 60  
       inhibition of, 61  
       intravenous hormones in, 41  
       laminaria in, 40  
       local hormones in, 40-41  
       prostaglandins in, 23, 41-44, 60-61, 96-98  
       relaxin in, 40, 60  
     in puerperium, 11-13  
     submucous fibroids affecting, 13  
     vascular patterns of, 939-944  
 Cesarean section  
   in immune thrombocytopenic purpura, 541-542  
   in intestinal obstruction, 837  
   in traumatic injuries, 907  
 Chancroid, 138-140  
   causative agent in, 138  
   clinical features of, 139  
   diagnosis of, 139-140  
   epidemiology of, 138  
   treatment of, 140  
 Chemicals  
   in breast milk, 461-466  
   placental transport of, 383-385  
   as reproductive hazard, 427, 429-435  
 Chest injuries in pregnancy, 906  
 Chlamydial infections, 143-160  
   acute urethral syndrome in, 148-149  
   bartholinitis in, 147-148  
   causative agents in, 143-145  
   cervicitis in, 148  
   cultures in, 159-160  
   cytology in, 159  
   diagnosis of, 158-160  
   endometritis in, 148  
   epidemiology and transmission of, 145-146  
   in females, 147-154

## CUMULATIVE INDEX

Chlamydial infections, (*continued*)  
 Fitz-Hugh-Curtis syndrome in, 152-154  
 in males, 146-147  
 neonatal, 154-158  
   conjunctivitis in, 155  
   pneumonia in, 155-156  
   prevention of, 156-158  
 in pregnancy, 158, 403  
 salpingitis in, acute, 149-152  
 serologic tests in, 159  
   treatment of, 160

Chloramphenicol, 393  
   in pregnancy, toxicity of, 400

Chloride deficiency, in infants, 459

Chloroquine in pregnancy  
   in autoimmune diseases, 639  
   in rheumatoid arthritis, 572

Cholecystitis in pregnancy, 816-818

Cholestasis, intrahepatic, in pregnancy, 813-814

Chondroitin sulfate, 15

Chorionic gonadotropin, 526  
   and luteal rescue in fertile cycle, 665-666

Chromosome abnormalities, in ovarian failure  
   syndromes, 694-695

Cigarette smoking. *See* Smoking

Cirrhosis, in pregnancy, 816

Clindamycin, 393  
   in pregnancy, 399  
   toxicity of, 401

Clotrimazole, in candidiasis, 195

Clue cells, in vaginal discharge, 191-192

Coagulation, in pregnancy, 914

Coagulator, cold, in cervical intraepithelial neoplasia, 996-1005

Cold coagulator, in cervical intraepithelial neoplasia, 996-1005

Colistin, 393

Colitis  
   Crohn's, in pregnancy, 824  
   ulcerative, 823-824  
     fertility affected by, 824-825  
     medical and surgical treatment of, 827-829  
     in pregnancy, 826

Collagen, 15  
   cervical, 8, 18  
     in pregnancy, 10, 19-20, 38  
     interaction with proteoglycans, 17

Collagenase, 17  
   cervical, 21-22

Colpophotography, of vascular changes in cervical intraepithelial neoplasia, 939

Colposcopy  
   and cervicography, 1007-1015  
   in condylomas of cervix, 950-953

Complement levels, in lupus erythematosus in pregnancy, 552-553

Condylomas, cervical, 949-964  
   colposcopy of, 950-953  
   cytology of, 950  
   electron microscopy of, 958-961  
   histology of, 953-955  
   immunoperoxidase studies of, 956-958  
   microspectrophotometry of, 955-956  
   in pregnancy, 964  
   treatment of, 963-964

Conjunctivitis, neonatal, in chlamydial infection, 155

Contraception  
   and gonorrhea prevention, 113-114  
   intrauterine devices in, location and retrieval with hysteroscopy, 228, 270-272, 280-281, 303  
   in lupus erythematosus, 554

Contraceptives, oral  
   in dysmenorrhea, 722-723  
   in premenstrual syndrome, 712

Contractions of uterus. *See* Uterus, contractile  
   activity of

Corpus luteum, 660-667  
   of pregnancy, 666

Corticosteroid therapy  
   in Crohn's disease, 829  
   in pregnancy  
     in autoimmune diseases, 638-639  
     in herpes gestationis, 612  
     in immune thrombocytopenic purpura, 543  
     in lupus erythematosus, 553  
     in myasthenia gravis, 599  
     in polyarteritis nodosa, 585  
     in rheumatoid arthritis, 573-574  
     in ulcerative colitis, 828

Cortisol, fetal levels of, 49

Counselling  
   genetic, in fetoscopy program, 340  
   of pregnant patients exposed to harmful agents, 478-483, 498-505

Craniopharyngioma  
   amenorrhea in, 752  
   menarchal delay in, 693

Crohn's disease, 824  
   fertility affected by, 825-826  
   medical and surgical treatment of, 829-830  
   in pregnancy, 826-827

Cushing's syndrome  
   amenorrhea in, 754-755  
   menarchal delay in, 693  
   in pregnancy, 883

Cyclophosphamide in pregnancy  
   in polyarteritis nodosa, 585  
   in rheumatoid arthritis, 572-573

Cycloserine, 392-393

Cystitis, in pregnancy, 402

Cystometrogram  
   normal findings in, 357

## CUMULATIVE INDEX

Cystometrogram (*continued*)  
procedure for, 351

Cystoscopy, historical aspects of, 347

Cytology  
in condylomas of cervix, 950  
negative results in, cervical cancer with, 929-936

Cytomegalovirus infection, 173-176  
congenital, 174  
epidemiology of, 174-176  
and heterophil-negative mononucleosis, 173  
and interstitial pneumonitis in infants, 174  
and neonatal sepsis, 174  
after renal and cardiac transplants, 173-174

DBCP, as hazard to reproduction, 433

DDT  
in breast milk, 465  
as hazard to reproduction, 433

Dermatan sulfate, 17  
cervical, 18  
in pregnancy, 20-21

Dermatitis  
gonococcal, 117  
herpetiformis, in pregnancy, 606

Desoxycorticosterone secretion, in pregnancy, 892

Dextran, as medium for hysteroscopy, 254, 259-262, 277-283

Dextrose in water, as medium for hysteroscopy, 254, 262

Diazoxide, in inhibition of labor, 65

Diethylstilbestrol, as hazard to reproduction, 433

Dilatation and curettage, in abnormal uterine bleeding, 249, 266, 704-705

Diphenylhydantoin in pregnancy, affecting fetus, 427, 433

Disinfection of laparoscopes, 335-337

Diuretics, in premenstrual syndrome, 711-712

Diverticula, urethral, 356-357

Donovan bodies, in granuloma inguinale, 140

Dopamine  
effects in menstrual cycle, 780-781  
and prolactin secretion, 673-736

Doxycycline, in gonorrhea, 120

Drug use in pregnancy, 377-476  
absorption of, 380  
antibiotics, 391-405  
biotransformation of  
maternal, 381-382  
prenatal, 386-387  
elimination of, 382-383  
epidemiologic aspects of, 418-427  
excretion in breast milk, 396, 461-466  
localization in fetus, 385-386  
maternal distribution of, 380-381  
pharmacokinetic aspects of, 379-389  
placental transport of, 383-385  
and relative risk concept, 420-421

Dysgerminomas of ovary, in pregnancy, 848-849

Dysmenorrhea, 719-727  
biologic mechanisms in, 720-722  
clinical features of, 719-720  
diagnosis of, 720  
primary, 719-725  
management of, 722-725  
prostaglandin production in, 721-722, 725  
secondary, 725-726  
treatment of, 725-726  
vasopressin secretion in, 781

Eclampsia of pregnancy, liver in, 812

Elastase, 17-18  
cervical, 22

Elastin, 15  
cervical, 9-18  
in pregnancy, 21

Electrocoagulation, in sterilization by laparoscopy, 324-325

Electromagnetic radiation, prenatal exposure to, 505-506

Embolism, pulmonary, in pregnancy, 913-921

Embryoscopy. *See* Fetoscopy

Endocarditis, infective, and antibiotic prophylaxis in pregnancy, 403-404

Endocrine disorders in pregnancy, 865-887  
adrenal, 888-884  
fetal effects of, 867  
gastrointestinal hormone hyperfunction, 884-885  
maternal effects of, 867  
multiple adenopathy, 885-887  
parathyroid, 873-876  
pheochromocytoma, 876-882  
pituitary, 885  
thyroid, 869-873  
and treatment affecting maternal/fetal unit, 868-869

Endometrium  
ablation of, in abnormal uterine bleeding, 249, 369  
chlamydial endometritis, 148  
contact hysteroscopy of, 224-225  
in hyperplasia, 228  
in polyps, 227-228  
hyperplasia of  
contact hysteroscopy in, 228  
and postmenopausal bleeding, 773-774  
neoplasia of  
hysteroscopy in, 228-234, 249, 251, 275  
microhysteroscopy in, 292  
panoramic CO<sub>2</sub> hysteroscopy of, 247-251

Endorphins  
and gonadotropin secretion, 674-675, 713-715  
and menstrual dysfunction, 781  
and premenstrual syndrome, 713-715

Endoscopy, gynecologic, 211-376  
disinfection or sterilization of laparoscopes in,

## CUMULATIVE INDEX

Endoscopy, gynecologic (*continued*)  
 335-337  
 fetoscopy, 339-345  
 flexible fiberoptic endoscopes in, 215-217  
 hysteroscopy. *See* Hysteroscopy  
 laser beam in, 366-372  
 and optical physics, 213-218  
 and pelvic infection, 331, 334-338  
 photography in, 359-365  
 review questions on, 375-376  
 rigid endoscopes in, 213-215  
 and sterilization by laparoscopy, 321-332  
 of urethra and bladder, 347-358

Enema diagnosis, in intestinal obstruction in pregnancy, 836-837

Enteritis, regional, 824

Epididymitis, chlamydial, 147

Epstein-Barr virus, and rheumatoid arthritis, 563

Ergot alkaloids, in puerperium, 68-69

Erythema multiforme, in pregnancy, 606

Erythromycin, 393  
 in chlamydial infections, 160  
 in gonorrhea, 121  
 in granuloma inguinale, 142  
 in pregnancy, 399  
 toxicity of, 401  
 in syphilis, 134

Estrogen  
 as cervical priming agent, 23-24, 40-41, 60  
 and gonadotropin secretion, 667-668, 669-670  
 luteolytic action of, 663-665  
 ovarian production of, 648-650  
 placental synthesis of, 49

Ethambutol, in tuberculosis prophylaxis in pregnancy, 405

Ethanol. *See* Alcohol

Ethylene dibromide, as hazard to reproduction, 433-434

Exercise, and menstrual dysfunction, 728-734, 750-751

Facial features, in fetal alcohol syndrome, 439-440

Falling, in pregnancy, 903

Fallopian tubes  
 laparoscopic sterilization, 321-332  
 occlusive devices for reversible sterilization, 272, 282, 294-295, 313-320  
 salpingoscopy, 294

Family planning, in lupus erythematosus, 554-555

Fenoterol, in inhibition of labor, 63

Fertility  
 cold coagulation affecting, 1004-1005  
 Crohn's disease affecting, 825-826  
 dysfunctional uterine bleeding affecting, 707-708  
 in lupus erythematosus, 550  
 smoking affecting, 442-443  
 ulcerative colitis affecting, 824-825

$\alpha$ -Fetoprotein, 552-556

Fetoscopy, 339-345  
 contact hysteroscopy in, 234-235  
 fetal blood sampling in, 341-343  
 fetal skin biopsy in, 343  
 and genetic counselling, 340  
 microhysteroscopy in, 292-294  
 photography with, 364  
 results of, 343-344  
 technical aspects of, 340  
 ultrasonography with, 340  
 visualization procedure in, 340-341

Fetus  
 alcohol syndrome in, 437-440  
 biotransformation of drugs in, 386-387  
 blood sampling techniques, 341-343  
 drug distribution in, 385-386  
 in immune regulation of pregnancy, 531  
 skin biopsy in, 343  
 therapy for, 407-416  
 in cardiac problems, 415-416  
 in diaphragmatic hernia, 412  
 in growth retardation, 414  
 in hydrocephalus, 409-411  
 in hydronephrosis, 411  
 in hypothyroidism, 414  
 in infections, 414  
 in polyhydramnios, 415  
 in Rh immunization, 413-414  
 thyroid function assessment in, 626-627

Fiberoptic endoscopes, 215-217

Fibroadenoma of breast, in pregnancy, 858-860

Fibrocystic disease of breast, in pregnancy, 856-858

Fibroids of uterus  
 and postmenopausal bleeding, 773  
 submucous, cervical changes with, 13

Fibromuscular junction, cervical, 9

Fitz-Hugh-Curtis syndrome, 152-154

Flufenamic acid, in dysmenorrhea, 724

Follicle-stimulating hormone  
 and ovarian estrogen production, 648-650  
 secretion in different forms, 672

Follicular development, ovarian, hormonal control of, 648-659

Fractures, in pregnancy, 904, 910-911

Galactocele, in pregnancy, 854

Galactorrhea, in hyperprolactinemia, 740-741

Gallbladder disease in pregnancy, 816-818

*Gardnerella vaginalis*, 199

Gastrointestinal tract  
 bowel injuries in sterilization by laparoscopy, 330  
 hormone hyperfunction in pregnancy, 884-885  
 inflammatory bowel disease in pregnancy, 822-830  
 intestinal obstruction in pregnancy, 832-841  
 in pregnancy, 796-797

Gastroschisis, prenatal detection of, 411-412

## CUMULATIVE INDEX

Genetic counselling, in fetoscopy program, 340

Gentamicin, 393

- in pregnancy, 398
- toxicity of, 400

Germ cell tumors of ovary, in pregnancy, 848-849

Glycosaminoglycans, 15-17

- cervical, 18
- in pregnancy, 18, 20, 38

Gold therapy in pregnancy

- in autoimmune diseases, 639
- in rheumatoid arthritis, 570-571

Gonadotropin

- chorionic, 526
- and luteal rescue in fertile cycle, 665-666
- pituitary
- endorphins affecting secretion of, 672-673, 712-713
- neuroendocrine control of secretion of, 667-677
- releasing hormone, 667-669
- inhibition of, and amenorrhea, 749-750

Gonorrhea 111-122

- antigen detection in, 119
- causative organism in, 115
- complications of, 114-115
- cultures in, 118-119
- diagnosis of, 115-119
- disseminated infection in, 121
- epidemiology of, 112-115
- in females, 116-117
- historical aspects of, 111-112
- incidence of, 112-113
- laboratory tests in, 117
- in males, 115-116
- microscopic diagnosis of, 117-118
- penicillinase-producing organisms in, 115
- treatment of, 122
- in pregnancy, 115, 403
- risk factors for, 113-114
- serologic tests in, 118
- treatment of, 119-122
- in complicated disease, 121-122
- in extragenital disease, 121
- in penicillinase-producing *Neisseria gonorrhoeae* infection, 122
- in uncomplicated disease, 119-121

Granuloma inguinale, 140-142

- causative agent in, 140
- clinical features of, 141
- diagnosis of, 141-142
- epidemiology of, 140-141
- treatment of, 142

Granulosa cell tumors of ovary, in pregnancy, 849-851

Graves' disease in pregnancy, 615-633, 869-872

- diagnosis of, 619-621
- and evaluation of newborn, 628-631
- iodide therapy in, 870
- labor and delivery in, 627-628

Graves' disease in pregnancy (continued)

- and long-term outcome of children, 631-632
- and maternal-fetal thyroid relationship, 615-617
- pathogenesis of, 617-619
- propylthiouracil in, 621-623, 871
- radioiodine in, 623-625
- surgery in, 625-626, 871-872

Growth

- intrauterine retardation of
- prenatal therapy in, 414
- from radiation exposure, 488-492
- perinatal
- in babies of smokers, 445
- in fetal alcohol syndrome, 439

Gunshot wounds, abdominal, in pregnancy, 903-904, 910

Halothane, hepatitis from, 183-184

Head injuries in pregnancy, 906

Heart

- failure of, fetal, treatment of, 416
- transplantation of, cytomegalovirus infection after, 173-174

Hematoporphyrin derivative, in photoradiation therapy, 372

Hematuria, in pregnancy, 898

*Haemophilus ducreyi*, 138

Hemorrhage, postpartum, contact hysteroscopy in, 237

Heparan sulfate, 17

- cervical, 18

Heparin therapy, in pregnancy, 917-919

Hepatitis, 178-184

- clinical aspects of, 178-179
- drug-related, 183-184
- management of, 179
- posttransfusion, 183
- in pregnancy, 182
- prophylaxis of, 179-180
- sequelae of type B, 182-183
- serology of, 180-181
- sexual transmission of, 181-182

Hernia, diaphragmatic, fetal surgery in, 412

Herpesvirus infection, 165-171

- characteristics of organisms in, 165
- clinical features of, 167-168
- complications of, 168
- diagnosis of, 169
- epidemiology of, 165-167
- gestationis, 605-612
- autoimmune factors in, 610-611
- clinical features of, 606-607
- fetal involvement in, 611-612
- histology of, 607-608
- hormonal factors in, 610
- lesion production in, 608-610
- treatment of, 612

## CUMULATIVE INDEX

Herpesvirus infection, gestationis (*continued*)  
 immune response to, 169  
 long-term sequelae of, 170-171  
 nonprimary, first-episode, 167-168  
 primary, first-episode, 167  
 recurrent, 167-168  
   ganglion theory of, 168  
   skin trigger theory of, 168  
 transmission to fetus, 170  
 treatment of, 169-170

Hexachlorobenzene, as hazard to reproduction, 434

Hexoprenaline, in inhibition of labor, 63

HLA antigen  
   in Graves' disease, 617  
   in herpes gestationis, 611  
   in pregnancy, 530  
   in rheumatoid arthritis, 562-563

Hulka clips, for sterilization by laparoscopy, 326-327

Hunter, Charles A, 5

Hyaluronic acid, 17  
   cervical, 18  
   in pregnancy, 19

Hydatidiform mole, contact hysteroscopy in, 235-237

Hydrocephalus, fetal therapy in, 409-411

Hydronephrosis  
   acute, in pregnancy, 898  
   fetal surgery in, 411

Hydroxychloroquine in pregnancy, in rheumatoid arthritis, 572

17 $\alpha$ -Hydroxylase, placental, and initiation of labor, 48-49

Hyperemesis gravidarum, and biliary tract disease, 813

Hyperparathyroidism in pregnancy, 875

Hyperplasia  
   adrenal, congenital, menarchal delay in, 691  
   endometrial  
     contact hysteroscopy of, 228  
     and postmenopausal bleeding, 770-771

Hypertension  
   in pheochromocytoma in pregnancy, 876-882  
   portal, in pregnancy, 816

Hyperthyroidism. *See* Graves' disease in pregnancy

Hypoglycemia, premenstrual syndrome in, 712

Hypogonadism  
   hypergonadotropic, 694-695  
   hypogonadotropic, 691-694  
     irreversible, 693-694  
     reversible, 692-693

Hypoparathyroidism in pregnancy, 875-876

Hypothalamus  
   diseases with hyperprolactinemia, 738  
   dysfunction with amenorrhea, 749-752  
   and gonadotropin secretion, 671  
   maturational arrest in, 691-694  
     irreversible, 693-694  
     reversible, 692-693

Hypothyroidism  
   fetal, treatment of, 414  
   hyperprolactinemia in, 739  
   menarchal delay in, 693

Hysterosalpingography  
   abnormal, confirmed by hysteroscopy, 267-270  
   compared to hysteroscopy, 302

Hysteroscopy  
   in abnormal uterine bleeding, 249, 266-267, 283  
   in adhesions of uterus, 270, 303-308  
   anesthesia in, 223, 244-245, 263  
   in Asherman's syndrome, 279-280  
   clinical applications of, 265-266  
   compared with hysterosalpingography, 302  
   complications from, 264-265  
   in confirmation of abnormal hysterosalpingograms, 267-270  
   contact, 219-240, 311  
     amnioscopy in, 239  
     anesthesia in, 223  
     in cervical neoplasia, 225-227  
     in children and infants, 239-240  
     dilatation of cervix in, 223  
     embryoscopy in, 234-235  
     in endometrial hyperplasia, 228  
     in endometrial neoplasia, 228-234  
     in endometrial polyps, 227-228  
     examination method in, 221-225  
     in hydatidiform mole, 235-237  
     in incomplete abortion, 237-238  
     in induced abortions, 239  
     instrumentation for, 217-218, 221  
     in intrauterine device localization, 228  
     light source for, 222-223  
     methods in, 220-221  
     normal endometrium in, 224-225  
     in postpartum hemorrhage, 237  
     in precursors to endometrial cancer, 230-231  
     in pregnancy, 234-239  
     in spontaneous abortion, 238-239  
     in submucous myomas, 228  
       technique of, 223-224  
     contraindications for, 264  
     diagnostic, 253-275  
     in endometrial neoplasia, 228-234, 249, 251, 275  
     in excision of endometrial polyps and submucous myomas, 251, 281-282, 308-310  
     indications for, 263-264  
     in infertility, 302-311  
     laser, 369  
     in location and removal of IUDs, 228, 270-272, 280-281, 303  
     microhysteroscopy, 285-300, 311. *See also* Microhysteroscopy  
     operative, 277-283  
       clinical applications of, 279-283

## CUMULATIVE INDEX

**Hysteroscopy (continued)**

- instrumentation in, 278
- panoramic
  - anesthesia in, 244-245
  - carbon dioxide in, 242-251, 254, 262
  - dextran in, 254, 259-262, 277-283, 311, 316
  - dextrose in water in, 254, 262
  - in endometrial neoplasia, 249, 251
  - in endometrial polyps, 251
  - historical aspects of, 253-254
  - instrumentation in, 244, 254-259
  - in submucous myomas, 249, 251
  - technique in, 245-251
- photography with, 364
- in resection of uterine septa, 282-283, 310
- technique in, 223-224, 245-251, 262-263
- in tubal occlusion with plugs, for sterilization, 272, 282, 294-295, 313-320
- in tubal sterilization, 282

**Ibuprofen, in dysmenorrhea, 724**

- Immune complex formation, in pregnancy, 528**
- Immune system in pregnancy, 521-533**
  - cellular immunity in, 528-532
  - and drug therapy in autoimmune diseases, 635-639
  - fecal regulation of, 531
  - and Graves' disease, 615-633
  - and herpes gestationis, 610-611
  - humoral immunity in, 527-528
  - impaired function of, 531-532
  - and lupus erythematosus, 547-555
  - and myasthenia gravis, 592-603
  - and polyarteritis nodosa, 579-585
  - and rheumatoid arthritis, 558-575
  - and scleroderma, 587-591

**Immune thrombocytopenic purpura, 537-544**

- Immunization, in hepatitis, 179-180**
- Immunoglobulin levels in pregnancy, 527-528**

**Immunosuppressive therapy in pregnancy**

- in autoimmune diseases, 639
- in lupus erythematosus, 554
- in polyarteritis nodosa, 585
- in rheumatoid arthritis, 572-573

**Incontinence, urinary, urethroscopy in, 352****Indomethacin**

- in dysmenorrhea, 724
- in inhibition of labor, 65-66
- in pregnancy, in autoimmune diseases, 637

**Infections**

- fetal, treatment of, 414
- from laparoscopy, 331, 334-338
- in pregnancy, 401-405
  - antibiotics in, 391-405
  - immune function in, 532

**Infertility**

- in dysfunctional uterine bleeding, 708

**Infertility (continued)**

- hysteroscopy in, 268, 302-311
- microhysteroscopy in, 292
- and tobacco use, 442-443
- Insulinoma in pregnancy, 885**
- Intestinal obstruction in pregnancy, 832-841**
  - diagnostic diagnosis of, 833-834
  - etiology of, 832-833
  - physical findings in, 834-835
  - postpartum, 838-839
  - pseudoobstruction, 839-841
  - radiologic and enema diagnosis of, 835-837
  - treatment of, 837-838
- Iodine therapy in Graves' disease in pregnancy, 870**
  - radioactive, 623-625
- Isoniazid in pregnancy**
  - toxicity of, 401
  - in tuberculosis prophylaxis, 404

**Jarisch-Herxheimer reaction, in therapy of syphilis, 135-136****Kallmann's syndrome**

- amenorrhea in, 752
- menarchal delay in, 693
- Kanamycin, 393**
  - in pregnancy, 398
  - toxicity of, 400
- Kepone, as hazard to reproduction, 434**
- Keratin sulfate, 15**
- Ketoconazole, in candidiasis, 196**
- Ketoprofen, in dysmenorrhea, 724**
- Kidney**
  - disorders in pregnancy, 890-890
  - in pregnancy, 796
  - transplantation of
    - cytomegalovirus infection after, 173-174
    - pregnancy alter, 899-900

**Labor and delivery**

- cervical changes in, 11, 20**
- in Graves' disease, 627-628**
- inhibition of, 63-66**
  - beta-receptor agonists in, 63-64
  - calcium antagonists in, 64-65
  - ethanol in, 64
  - magnesium sulfate in, 65
  - progesterone in, 66
  - prostaglandin synthetase inhibitors in, 65-66
- initiation of, spontaneous, 47-54**
  - and placental 17 $\alpha$ -hydroxylase activity, 48-49
  - prostaglandins in, 50-54
  - species differences in, 47-50
- in lupus erythematosus, 553**
- in myasthenia gravis, 597-598**
- oxytocin-induced, 61-62**

## CUMULATIVE INDEX

Labor and delivery, oxytocin-induced (*continued*)
   
 combined with prostaglandin-gel, 101
   
 compared to prostaglandins, 91-93, 98
   
 pharmacologic induction of, 61-63
   
 oxytocin in, 61-62
   
 prostaglandins in, 62-63
   
 pharmacology of, 56-71
   
 and control of cervical state, 59-61
   
 and control of uterine activity, 56-59
   
 and induction of labor, 61-63
   
 and inhibition of labor, 63-66
   
 and postpartum period, 66
   
 prostaglandin-induced, 62-63
   
 cervical dilatation pattern in, 88-89
   
 combined with oxytocin, 101
   
 compared with oxytocin, 91-93, 98
   
 efficacy of, 87-88
   
 intracervical application in, 95-103
   
 intravaginal administration of, 102
   
 new gel formulations in, 99-100
   
 orally administered, 87-93
   
 side effects of, 90-91
   
 uterine activity in, 89-90
   
 in rheumatoid arthritis, 575
   
 in thrombocytopenic purpura, immune, 541-543

*Lactobacilli*, in vaginal discharge, 191

Lactogen, placental, 526

Laminaria, for cervical ripening, 40

Laparoscopy
   
 infection from, 331, 334-338
   
 laser, 367-369
   
 photography with, 364
   
 in tubal sterilization, 321-332

Laser endoscopy, 366-372
   
 in hysteroscopy, 369
   
 in laparoscopy, 367-369
   
 and photoradiation therapy in tumors, 372
   
 properties of laser in, 366-367
   
 tissue action in, 367, 982

Laser therapy in cervical intraepithelial neoplasia, 980-994
   
 anesthesia in, 985
   
 combination excision conization and vaporization in, 990-991
   
 complications of, 991
   
 excisional cone in, 988-990
   
 healing after, 988
   
 preparation of patient for, 984
   
 results of, 991-993
   
 safety of, 983-984
   
 sensation during, 988
   
 tissue action in, 982
   
 vaporization technique in, 985-988

Lead, exposure to, as hazard to reproduction, 434

Leukemia, from prenatal radiation exposure, 493-497

Leukocytes, in vaginal discharge, 191

Leukocytosis, in appendicitis in pregnancy, 804

Lincomycin, 393

Lithium therapy in pregnancy, affecting fetus, 422-423

Liver
   
 disorders in pregnancy
   
 acute fatty liver, 811-812
   
 amebic abscess, 814-815
   
 in preeclampsia/eclampsia, 812
   
 rupture, 812-813
   
 in pregnancy, 810-811

Lupus erythematosus in pregnancy, 547-555
   
 diagnosis of, 547-549
   
 and effects of pregnancy termination, 549-550
   
 and family planning, 554-555
   
 fetoplacental effects of, 550-552
   
 management of, 552-554
   
 maternal effects of, 550

Luteal phase of menstrual cycle, 660-667

Luteinizing hormone
   
 receptors in corpus luteum, 663
   
 secretion in different forms, 672
   
 surge in menstrual cycle, 656, 658-659

Luteolysis, mechanisms in, 662-665

Lymphocyte activity, in pregnancy, 528-530

Magnesium sulfate, in inhibition of labor, 65

Malnutrition, in infants, 459-460

Marijuana, in breast milk, 465

Mastitis, in pregnancy, 854-855

Mefenamic acid, in dysmenorrhea, 724

Menarche, exercise affecting, 728-730

Menopause
   
 and benign postmenopausal bleeding, 769-776
   
 in atrophic vaginitis, 770-771
   
 in cervical erosions, 774
   
 in cervical polyps, 771-773
   
 in endometrial hyperplasia, 773-774
   
 in fibroids, 773
   
 in ovarian tumors, 774-775
   
 in pyometra, 775-776
   
 in vaginal adenosis, 775
   
 perimenopausal problems, 762
   
 diagnosis of, 766
   
 endocrine changes in, 762-764
   
 pathophysiology of, 764-766
   
 treatment of, 768-764, 766-767

Menorrhagia, hysteroscopy in, 283

Menstrual cycle
   
 endocrine characteristics of, 647-677
   
 follicular development in, 648-659
   
 luteal phase in, 660-667

Menstruation
   
 and abnormal bleeding, 702-709. *See also Uterus*,
   
 abnormal bleeding from
   
 adolescent disorders in, 690-700
   
 anatomic abnormalities in, 695-696

## CUMULATIVE INDEX

Menstruation, adolescent disorders in (*continued*)  
 androgen sensitivity in, 696  
 in eugonal pubertal defects, 695  
 evaluation and management of, 698-700  
 in gonadal failure, 694-695  
 in hypothalamic-pituitary maturation arrest, 691-694  
 inappropriate positive feedback in, 696  
 organic causes of, 697  
 and amenorrhea, 749-757  
 benign postmenopausal bleeding, 769-776  
 dysmenorrhea, 719-726  
 exercise affecting, 728-734, 750-751  
 in hyperprolactinemia, 736-747  
 and perimenopausal problems, 762-767  
 and premenstrual syndrome, 710-718  
 psychosomatic aspects of dysfunction in, 733, 751, 777-782

Mental retardation  
 in fetal alcohol syndrome, 439  
 from prenatal radiation exposure, 488-489

Methylmercury, as hazard to reproduction, 434

Metronidazole  
 in pregnancy, toxicity of, 401  
 in trichomoniasis, 197-199

Miconazole, in candidiasis, 195

Microcephaly  
 in fetal alcohol syndrome, 439  
 from prenatal radiation exposure, 488-492

Microcolposcopy, 290-291, 295-300

Microhysteroscopy, 285-300, 311  
 in abnormal uterine bleeding, 292  
 complications and failures with, 291-292  
 contraindications for, 291  
 in infertility, 292  
 instrumentation in, 285-288  
 normal findings in, 292  
 operative indications for, 294-295  
 in pregnancy, 292-294  
 technique of, 288-291

Microspectrophotometry, of condylomas of cervix, 955-956

Microwave exposure in pregnancy, 505-506

Mineral deficiencies, in infants, 459

Mineralocorticoid secretion, in pregnancy, 892

Minocycline, in gonorrhea, 120

Mole, hydatidiform, contact hysteroscopy in, 235-237

Mononucleosis, heterophil-negative, 173

Montevideo unit, for uterine activity, 88

Muscle, cervical, 9-10

Myasthenia gravis, 592-603  
 anticholinesterase drugs in, 598  
 corticosteroids in, 598-599  
 crisis in, 600  
 diagnosis of, 592-593  
 and drugs enhancing muscle weakness, 600-601

Myasthenia gravis (*continued*)  
 immunopathology of, 593-594  
 neonatal, 601-602  
 plasmapheresis in, 599  
 in pregnancy, 594-600  
 analgesia and anesthesia in, 597-598  
 thymectomy in, 599-600

Mycelia, in vaginal discharge, 192

Myomas of uterus, submucous  
 contact hysteroscopy in, 228  
 excision with hysteroscopy, 251, 281-282, 308-310  
 excision with microhysteroscopy, 294  
 panoramic CO<sub>2</sub> hysteroscopy in, 249, 251

Myosin filaments, in uterine contractile activity, 51, 78

Nalidixic acid, 393

Naproxen sodium, in dysmenorrhea, 724

*Neisseria gonorrhoeae*, 115

penicillinase-producing, 115  
 treatment of, 122

Neomycin, 393

Neostigmine, in myasthenia gravis, 598

Nervous system, in pregnancy, 797

Neural tube defects, fetal therapy in, 409-411

Neurotransmitters  
 and menstrual cycle disorders, 780  
 and secretion of gonadotropin releasing hormone, 672-674

Newborn  
 chlamydial infection in, 154-158  
 herpesvirus infection in, 170  
 myasthenia gravis in, 601-602

Nifedipine  
 in inhibition of labor, 65  
 reducing uterine contractions, 68

Nitrofurantoin, in pregnancy, 399  
 toxicity of, 400-401

Novobiocin, 393

Nutrition of infants  
 and drugs and chemicals in breast milk, 396, 461-466  
 and food environmental hazards, 458-461

Nystatin, 393  
 in candidiasis, 195

Occupational exposure to chemicals, as hazard to reproduction, 427, 429-435, 450-451, 465, 480

Ogilvie's syndrome, 839-841

Omphalocele, prenatal detection of, 411-412

Oocyte maturation inhibitor, 658

Ovaries  
 disorders in pregnancy, 843-851  
 cancer, 846-848  
 dysgerminomas, 848-849  
 granulosa cell tumors, 849-851  
 torsion, 843-845

## CUMULATIVE INDEX

Ovaries (*continued*)

- failure of
  - amenorrhea in, 753-754
  - competent, 695
  - incompetent, 694-695
- follicles of
  - antral, 650-651
  - dominant, selection of, 651-653
  - feedback mechanisms affecting, 654-655
  - hormonal control of development, 648-659
  - luteal suppression of new growth, 661-662
  - preantral, 648-650
  - preovulatory, 656-657
  - primordial, 648
- polycystic syndrome of, amenorrhea in, 752
- pregnancy in, 845-846
- tumors of, and postmenopausal bleeding, 771-772

Ovulation, 657-659

- and anovulation in hyperprolactinemia, 741-742
- detection of, 705
- selection of dominant follicle in, 651-653

Oxytocin

- as cervical priming agent, 41
- in labor induction, 61-62
- combined with prostaglandin-gel, 101
- compared to prostaglandins, 91-93, 98
- in postpartum uterine atony, 69-70

## Pain

- in appendicitis, 802-803
- in intestinal obstruction in pregnancy, 834
- Papanicolaou smears
  - and cervical cancer with negative cytology, 929-936
  - in condylomas of cervix, 950
- Papillomavirus infections, cervical lesions in, 949-964
  - See also* Condylomas, cervical
- Parathyroid disorders in pregnancy, 873-876
  - fetal effects of, 876
  - hyperparathyroidism, 875
  - hypoparathyroidism, 875-876
- PCBs
  - in breast milk, 465
  - as hazard to reproduction, 434
- Pelvic inflammatory disease, gonococcal, 115, 121
- Pemphigoid, bullous, in pregnancy, 606
- Penicillamine in pregnancy
  - in rheumatoid arthritis, 572
  - in scleroderma, 591
- Penicillin, 393
  - in gonorrhea, 120
  - in pregnancy, 397-398
  - in syphilis, 132-135
- Penicillinase-producing *Neisseria gonorrhoeae*, 115
  - treatment of, 122
- Pesticides, as hazard to reproduction, 434

Pharmacology of pregnancy. *See* Drug use in pregnancy

Pharyngitis, gonococcal, 121

Phenothiazines in pregnancy, affecting fetus, 426

Pheochromocytoma in pregnancy, 876-882

diagnosis of, 878-880

hypertension in, 876-882

and outcome of pregnancy, 881-882

treatment of, 880-881

Photography, endoscopic, 359-365

equipment for, 360-364

in fetoscopy, 364

in hysteroscopy, 364

in laparoscopy, 364

in urethroscopy, 364

Photoradiation surgery, in tumors, 372

## Pituitary

defects with amenorrhea, 752-753

disorders in pregnancy, 885

gonadotropi secretion, neuroendocrine control of, 667-677

maturational arrest in, 691-694

irreversible, 693-694

reversible, 692-693

tumors of, hyperprolactinemia in, 739

## Placenta

abruptio, in traumatic injuries, 907-908

17 $\alpha$ -hydroxylase in, and initiation of labor, 48-49

transport of drugs and chemicals in, 383-385

antibiotics, 395-396

Placental lactogen, 526

## Plasmapheresis

in myasthenia gravis, 599

in rheumatoid arthritis, 574

Plethysmography, impedance, in pregnancy, 916

Pneumonia, neonatal, in chlamydial infection, 155-156

Pneumonitis, interstitial, in infants, and cytomegalovirus infection, 174

Polyarteritis nodosa, 579-585

clinical features of, 579-581

cutaneous, 582

diagnosis of, 578

pathology of, 579

in pregnancy, 582-585

treatment of, 581-582

Polyhydramnios, amniocentesis in, 415

Polymyxins, 393

## Polyps

cervical, 771-773

endometrial

contact hysteroscopy in, 227-228

excision with hysteroscopy, 251, 281-308

excision with microhysteroscopy, 294

panoramic CO<sub>2</sub> hysteroscopy in, 251

Postpartum period. *See* Puerperium

## CUMULATIVE INDEX

Prednisone in pregnancy, affecting fetus, 423  
 Preeclampsia, liver in, 812  
 Pregnancy  
     after sterilization procedures, 327-329  
     alcohol consumption in, 437-442  
     anesthesia in, 795-800  
     antibiotics in, 391-405  
     appendicitis in, 801-809  
     autoimmune diseases in, drug therapy in, 635-639  
     biliary tract disease in, 810-818  
     blood volume in, 522-523  
     breast disease in, 853-863  
     cervical changes in, 10-11, 18-22  
     chlamydial infection in, 158, 403  
     condylomas of cervix in, 964  
     cone biopsy of cervix in, 976-977  
     contact hysteroscopy in, 234-239  
     endocarditis prophylaxis in, 403-404  
     endocrine disorders in, 865-887  
     and fetal therapy, 407-416  
     fetoscopy in, 339-345  
     gonorrhea in, 403  
     Graves' disease in, 615-633, 869-872  
     hepatitis in, 182  
     herpesvirus infection in, 170, 605-612  
     in hyperprolactinemia, 746-747  
     immune system in, 521-533  
     immune thrombocytopenic purpura in, 539-544  
     infections in, treatment of, 401-405  
     inflammatory bowel disease in, 822-830  
     lupus erythematosus in, 547-555  
     microhysteroscopy in, 292-294  
     molar, contact hysteroscopy in, 235-237  
     myasthenia gravis in, 594-600  
     ovarian, 845-846  
     ovarian disorders in, 843-851  
     plasma proteins in, 524-526  
     polyarteritis nodosa in, 582-585  
     prolactin levels in, 737  
     rheumatoid arthritis in, 567-575  
     scleroderma in, 589-591  
     smoking in, 442-446  
     syphilis in, 128-129, 403  
     and teratogenesis. *See* Toxicology of pregnancy  
     thromboembolic complications of, 913-921  
     tuberculosis in, prophylaxis for, 404-405  
     urinary tract infections in, 401-403, 890-900  
 Premature labor  
     anesthesia related to, 798  
     and delay of delivery, 414  
     in myasthenia gravis, 595-596  
     prevention in appendectomy, 807  
     in thrombocytopenic purpura, immune, 541  
 Premenstrual syndrome, 710-718  
     early identification of, 715  
     and endogenous hormone allergy, 712  
 Premenstrual syndrome (*continued*)  
     endorphin activity in, 713-715  
     in hypoglycemia, 712  
     management of, 715-717  
     progesterone insufficiency in, 710  
     symptoms of, 709-710  
     in vitamin B<sub>6</sub> deficiency, 712  
 Proctocolectomy, in ulcerative colitis, 829  
 Progesterone  
     and gonadotropin secretion, 670  
     inhibiting follicular growth, 661-662  
     in inhibition of labor, 66  
     insufficiency of, and premenstrual syndrome, 710  
     and maternal immune response, 527  
     placental synthesis of, 49  
     as therapy in premenstrual syndrome, 716-717  
 Prolactin  
     biologic action of, 738  
     and gonadotropin secretion, 673-674  
     hyperprolactinemia, 736-747  
     anovulation in, 741-742  
     bromocriptine in, 743, 745-747  
     causes of, 738-740  
     clinical features of, 740-741  
     in disorders of inhibitory control, 738  
     drug-induced, 740  
     in endocrine-related disorders, 739-740  
     evaluation of, 742-743  
     in pituitary tumors, 739  
     pregnancy in, 746-747  
     stress-induced, 781-782  
     surgery in, 743  
     and luteal function, 666-667  
     neuroregulation of, 736-737  
     physiologic secretion of, 737-738  
 Prolactinomas, pubertal menstrual disorders in, 694  
 Propylthiouracil, in Graves' disease in pregnancy, 621-623, 871  
 Prostaglandin(s)  
     as cervical priming agents, 23, 41-44, 60-61, 96-98  
     effects on uterus, 53-54  
     and labor initiation, spontaneous, 50-54  
     in pharmacologic induction of labor, 62-63. *See also*  
         Labor, prostaglandin-induced  
     in postpartum uterine atony, 70-71  
     production in dysmenorrhea, 721-722, 725  
     synthesis in corpus luteum, 663  
     uterine synthesis of, 50-51  
         control of, 51  
         inhibition of, 51-52  
         stimulation of, 52-53  
 Prostaglandin synthetase inhibitors  
     in dysmenorrhea, 723-724  
     in inhibition of labor, 65-66  
 Proteins, plasma, pregnancy-associated, 524-526  
 Proteoglycans, 15-17

## CUMULATIVE INDEX

Proteoglycans (*continued*)  
 cervical, 18  
   in pregnancy, 20-21  
 Pseudoobstruction of colon, 839-841  
 Psychologic aspects of menstrual dysfunction, 777-782  
   in amenorrhea, 733, 751, 780  
 Pubertal development, abnormalities in, 689-694, 691-696  
 Puerperium  
   cervical changes in, 11-13  
   ergot alkaloids in, 68-69  
   oxytocin in, 69-70  
   pharmacology of, 66-71  
   prostaglandins in, 70-71  
   uterine contractions in, 67-68  
 Purpura, immune thrombocytopenic, 537-544  
 Pyelonephritis in pregnancy, 402-403, 895-897  
 Pyometra, and postmenopausal bleeding, 775-776  
 Pyridoxine  
   deficiency of, premenstrual syndrome in, 712  
   as therapy in premenstrual syndrome, 716-717  
 Radiation exposure, prenatal, 484-505, 894  
   carcinogenic effects of, 498-498  
   and counselling of patients, 498-505  
   teratogenic effects of, 486-505  
 Radioiodine, in Graves' disease in pregnancy, 623-625  
 Radiology  
   in intestinal obstruction in pregnancy, 835-836  
   in rheumatoid arthritis, 565-566  
 Reiter's syndrome, chlamydial infection in, 147  
 Relaxin, as cervical priming agent, 40  
 Renography, isotope, in pregnancy, 895  
 Respiratory system, in pregnancy, 796  
 Rh immunization, intrauterine transfusions in, 418-414  
 Rheumatoid arthritis, 558-575  
   autoimmune mechanisms in, 561  
   clinical features of, 563-565  
   criteria for diagnosis of, 559-560  
   differential diagnosis of, 566-567  
   Epstein-Barr virus in, 563  
   genetic factors in, 562-563  
   immunopathogenesis of, 560-561  
   laboratory findings in, 566  
   in pregnancy, 567-575  
     chloroquine in, 571-572  
     corticosteroids in, 573-574  
     delivery in, 575  
     gold therapy in, 570-571  
     immunosuppressive therapy in, 572-573  
     management of, 569-575  
     nonsteroidal antiinflammatory agents in, 570  
     penicillamine in, 572  
     remissions in, 568-569  
     salicylates in, 569-570  
 Rheumatoid arthritis, (*continued*)  
   radiology in, 565-566  
   rheumatoid factors in, 561-562  
 Rifampin, 393-394  
   in tuberculosis prophylaxis in pregnancy, 405  
 Ritodrine, in inhibition of labor, 63  
 Rubella vaccine in pregnancy, affecting fetus, 422  
 Salbutamol, in inhibition of labor, 63  
 Salicylates in pregnancy  
   in autoimmune diseases, 635-637  
   in rheumatoid arthritis, 569-570  
 Salpingitis, acute  
   chlamydial, 149-152  
   in Fitz-Hugh-Curtis syndrome, 152-154  
 Salpingoscopy, 294  
 Salt intake in pregnancy, 892  
 Scleroderma, 587-591  
   clinical features of, 587-588  
   diagnosis of, 588-589  
   in pregnancy, 589-591  
 Semm cold coagulator, in cervical intraepithelial neoplasia, 996-1005  
   advantages and disadvantages of, 1005  
   complications of, 1004  
   effectiveness of, 1002-1004  
   fertility after, 1004-1005  
   follow-up in, 1002  
   patients suitable for, 998-999  
   technique of, 999  
 Serotonin, and prolactin release, 737  
 Sexual development, delayed, menstrual disorders in, 691-695  
 Sexually transmitted diseases, 109-204  
   chancroid, 138-140  
   chlamydial infections, 143-160  
   cytomegalovirus, 173-176  
   gonorrhea, 111-122  
   granuloma inguinale, 140-142  
   hepatitis, 178-184  
   herpesvirus infection, 165-171  
   review questions on, 203-204  
   syphilis, 125-136  
   vaginal discharge in, 186-200  
 Sheehan's syndrome, in pregnancy, 885  
 Sipple's syndrome in pregnancy, 886  
 Skin  
   biopsy of, fetal, 343  
   lesions of  
     in chancroid, 139  
     in gonorrhea, 117  
     in granuloma inguinale, 141  
     in syphilis, 126  
 Smoking  
   and infertility, 442-443  
   and nicotine in breast milk, 465

## CUMULATIVE INDEX

**Smoking (continued)**

- in pregnancy, 442-446
- complications from, 444-445
- fetal effects of, 434, 443-444
- and growth and development of infants, 445
- and outcome of pregnancy, 443
- and sudden infant death syndrome, 445-446

Sodium intake in pregnancy, 892

Solvents, exposure to, as hazard to reproduction, 427, 434

Streptomycin, 393

- in gonorrhea, 121

Spermicides, teratogenic effects of, 423-424

Splenectomy in pregnancy, in immune thrombocytopenic purpura, 541

Sports, and menstrual dysfunction, 728-734

Stab wounds in pregnancy, 904, 910

Sterilization, of laparoscopes, 335-337

Sterilization, tubal

- hysteroscopic, 282
- laparoscopic, 321-332
- anesthesia in, 322
- bipolar electrocoagulation in, 325
- bleeding from, 330-331
- complications from, 329-331
- contraindications for, 321
- electrothermal burns from, 330
- Hulka clips in, 326-327
- indications for, 321
- infection from, 331, 334-338
- pregnancy rates after, 327-329
- preoperative preparation in, 322
- preparation and draping in, 323
- reversibility of, 331
- silastic bands in, 325-326
- unipolar electrocoagulation in, 324-325

occlusive devices in, 272, 282, 294-295, 313-320

Streptomycin, 393

- in pregnancy, toxicity of, 400

Stress, and amenorrhea, 730, 733, 748, 751, 777, 780

Sudden infant death syndrome, maternal smoking as factor in, 445-446

Sulfasalazine

- in Crohn's disease, 829
- in ulcerative colitis, 828

Sulfisoxazole

- in chancroid, 140
- in chlamydial infections, 160

Sulfonamides, 392

- in pregnancy, 399
- toxicity of, 400

Surgery

- hysteroscopic, 277-283
- in pregnancy, and fetal outcome, 449-456
- sterilization by laparoscopy, 321-332

Surgical diseases in pregnancy

- anesthesia in, 795-800
- appendicitis, 801-809
- biliary tract disease, 810-818
- breast diseases, 853-863
- endocrine disorders, 865-887
- inflammatory bowel disease, 822-830
- intestinal obstruction, 832-841
- ovarian disorders, 843-851
- review questions on, 923-924
- thromboembolic disease, 913-921
- trauma, 902-912
- urinary tract disease, 890-900

Syphilis, 124-136

- causative agent in, 126
- congenital, 128-129
- serologic diagnosis of, 132
- dark-field microscopy in, 129, 130
- diagnosis of, 129-132
- fetal, treatment of, 414
- fluorescent treponemal antibody absorption test in, 127, 129-130, 131
- hemagglutination test in, 127, 131, 132
- incidence of, 127
- latent phase in, 126
- pathophysiology of, 127-128
- in pregnancy, 128-129, 403
- treatment of, 135
- primary, 126
- secondary, 126
- serologic tests for, 130-132
- tertiary or late, 126-127
- treatment of, 132-136
- Jarisch-Herxheimer reaction in, 135-136
- in pregnancy, 135-136

VDRL test in, 126, 130-131

Wassermann test in, 130

Teratogenesis. *See* Toxicology of pregnancy

Teratogenicity testing in animals, 467-476

and concordance of human and animal data, 468-470, 481

improvements needed in, 472-474

potential test systems in, 474-476

and sources of species differences, 471-472

Tetracyclines, 393

- in chlamydial infections, 160
- in gonorrhea, 120
- in granuloma inguinale, 142
- in pregnancy, toxicity of, 399-400
- in syphilis, 134

Thalidomide in pregnancy, affecting fetus, 484

Thrombocytopenic purpura, immune, 537-544

- clinical features of, 538-539
- pathophysiology of, 537-538
- in pregnancy, 539-544
- delivery in, 541-543

## CUMULATIVE INDEX

Thrombocytopenic purpura, immune, in pregnancy (*continued*)  
 fetal and neonatal morbidity in, 541  
 management of, 540-541, 543-544  
 maternal morbidity in, 540  
 treatment of, 539

Thromboembolic disease in pregnancy, 913-921  
 anticoagulants in, 917-919  
 diagnosis of, 914-916  
 pathophysiology of, 914  
 prophylactic therapy in, 919-920  
 surgery in, 920-921  
 thrombolytic therapy in, 920  
 treatment of, 916-921

Thrombolytic therapy, in pregnancy, 920

Thymectomy, in myasthenia gravis, 599-600

Thyroid disease  
 amenorrhea in, 755  
 Graves' disease in pregnancy, 615-633  
 hypothyroidism  
   hyperprolactinemia in, 739  
   menarchal delay in, 693  
 in pregnancy, 869-873  
   hyperthyroidism, 615-633, 869-872  
   nodules, 872-873

Thyroidectomy in pregnancy, 625-626, 872, 873

Thyrotropin releasing hormone, and prolactin secretion, 737

Tobacco use. *See Smoking*

Tobramycin, 398  
 in pregnancy, toxicity of, 400

Tocography, external, 80

Tolfenamic acid, in dysmenorrhea, 724

Toluene, as hazard to reproduction, 427, 434

Torsion of ovarian pedicle, in pregnancy, 843-845

Toxicology of pregnancy, 377-510  
 alcohol consumption, 437-442  
 anesthesia and surgery affecting fetal outcome, 449-456, 797-798  
 and animal teratogenicity testing, 467-476  
 and antibiotic use, 391-405  
 cigarette smoking, 442-446  
 and counseling of patients, 478-483, 498-505  
 and drugs and chemicals in breast milk, 461-466  
 and epidemiology of drug exposure, 418-427  
 and exposure to chemicals in workplace, 427, 429-435, 450-451, 465, 480  
 and fetal therapeutics, 407-416  
 microwave exposure, 505-506  
 pharmacokinetic aspects of, 379-389  
 radiation exposure, 484-505  
 ultrasound exposure, 505-506

Toxoplasmosis, fetal, treatment of, 414

Transfusions  
 hepatitis from, 183  
 intrauterine, in Rh immunization, 413-414

Transplantation  
 cardiac, cytomegalovirus infection after, 173-174  
 renal  
   cytomegalovirus infection after, 173-174  
   pregnancy after, 899-900

Trauma in pregnancy, 902-912  
 abdominal injuries, 906-907  
   penetrating, 903-904, 910  
 abruptio placentae in, 907-908  
 burns, 904, 911-912  
 cesarean section in, 907  
 falls, 903  
 fractures, 904, 910-911  
 head and chest injuries, 906  
 initial management of, 904-906  
 motor vehicle injuries, 903  
 urinary tract in, 909-910  
 uterine rupture in, 908-909

*Treponema pallidum*, 126

Trichomonads, in vaginal discharge, 191

Trichomoniasis, 197-199

Trimethadione in pregnancy, affecting fetus, 427

Trimethoprim, 392  
 in pregnancy, toxicity of, 401

Tuberculosis in pregnancy, prophylaxis in, 404-405

Tumors  
 breast cancer in pregnancy, 860-863  
 cervical  
   contact hysteroscopy in, 225-227  
   intraepithelial neoplasia, 925-1017  
   microcolposcopy in, 298-300  
   endometrial hysteroscopy of, 228-235, 249, 251, 275  
   multiple endocrine adenopathy in pregnancy, 885-887  
 ovarian, in pregnancy, 846-851  
   pheochromocytoma in pregnancy, 876-882  
   photoradiation therapy in, 372

Turner's syndrome, 694-695

Ultrasonography  
 affecting fetus, 506  
 and fetoscopy, 340  
 in thrombosis diagnosis in pregnancy, 915-916  
 of urinary tract in pregnancy, 894

Urethra  
 acute syndrome in females, 148-149  
 diverticula of, 356-357  
 endoscopy of, 347-358

Urethral syndrome, 352

Urethritis in males  
 gonococcal, 115-116  
 nongonococcal, 146-147

Urethroscopy, 347-358  
 in diverticula, 356-357  
 dynamic findings in, 352  
 historical aspects of, 347

## CUMULATIVE INDEX

**Urethroscopy (continued)**

- instrumentation in, 348
- photography with, 364
- technique of, 349-351
- in urethral syndrome, 352
- Urinalysis, in appendicitis in pregnancy, 804**
- Urinary tract**
  - disease in pregnancy, 890-900
  - calculi, 897-898
  - congenital anomalies, 898-899
  - diagnosis of, 893-895
  - and effective renal plasma flow, 890-891
  - glomerular filtration rate in, 891-892
  - hematuria, 898
  - hydronephrosis, acute, 898
  - infections, 401-403, 895-897
  - morphologic changes in, 892-893
  - and renal transplantation, 899-900
  - retention of urine, 899
  - sodium intake and mineralocorticoid secretion in, 892
  - injuries in pregnancy, 909-910
  - Urogenital malformations, fetal surgery in, 411**
  - Uterus**
    - abnormal bleeding from, 702, 709
    - ablation of endometrium in, 249, 369
    - and detection of ovulation, 705
    - differential diagnosis of, 704
    - dilatation and curettage in, 249, 266, 704, 705
    - in exercise and sports, 730, 733
    - history in, 702-704
    - hysteroscopy in, 249, 266-267, 283
    - infertility in, 708
    - laser hysteroscopy in, 369
    - microhysteroscopy in, 292
    - organic causes of, 705
    - pathologic bleeding in, 707-708
    - physiologic bleeding in, 706-707
    - postmenopausal, 769-776
    - adhesions of
      - hysteroscopy in, 270, 303-308
      - microhysteroscopy in, 294
    - cervical conditions. *See Cervix uteri*
    - contractile activity of, 78-85
      - activation of, 56-59
      - position of patient affecting, 81
      - in prostaglandin-induced labor, 89-90
      - in puerperium, 67-68
      - quantitation of, 83-85
    - disorders with amenorrhea, 754
    - endometrial hyperplasia, 773-774
    - fibroids of, and postmenopausal bleeding, 773
    - hysteroscopy of. *See Hysteroscopy*
    - intrauterine pressure measurements, 80
      - postpartum, 67
    - prostaglandins affecting, 53-54

**Uterus (continued)**

- rupture by trauma, in pregnancy, 908-909
- septate, hysteroscopy of, 282-283, 310

**Vagina**

- adenosis of, and postmenopausal bleeding, 775
- discharge from, 186-200
  - amine odor of, 190, 199
  - appearance of, 189-190
  - in candidiasis, 195-197
  - clue cells in, 191-192
  - components of, 186-189
  - cultures of, 193-194
  - lactobacilli in, 191
  - mycelia in, 192
  - in nonspecific vaginitis, 199-200
  - organisms in, 187
  - pH of, 190
  - physiologic, 194-195
  - trichomonads in, 191
  - in trichomoniasis, 197-199
  - white blood cells in, 191

**Vaginitis**

- atrophic, 781
- gonococcal, 116
- nonspecific, 199-200
- Valproic acid in pregnancy, affecting fetus, 426
- Vancomycin, 393
- Vascular changes, in cervical intraepithelial neoplasia, 938-948

**Vasculitis**

- in polyarteritis nodosa, 579
- in rheumatoid arthritis, 565

**Vasopressin secretion, stress affecting, 781****VDRL test for syphilis, 126, 130-131****Venereal diseases. *See Sexually transmitted diseases*****Vinyl chloride, as hazard to reproduction, 434****Vitamin deficiency**

- $B_6$  deficiency, premenstrual syndrome in, 712
- in infants, 459-460

**Vomiting in pregnancy**

- in appendicitis, 803-804
- in intestinal obstruction, 835
- and liver abnormalities in hyperemesis gravidarum, 813

**Warfarin therapy, in pregnancy, 918**

- affecting fetus, 434

**Wassermann test for syphilis, 130****Weight, and menstrual disorders, 732, 750****Wermer's syndrome in pregnancy, 885-886****Workplace, chemical hazards in, 427, 429-435, 450-451, 465, 480****Zinc deficiency, in infants, 459**



## AUTHOR INDEX

Amin, Hussein K., 277  
Andersson, K.-E., 56  
Baggish, Michael S., 211, 219, 366, 980  
Baker, David A., 165  
Barbot, Jacques, 219  
Benzie, Ronald J., 339  
Bohon, Constance J., 832  
Bolan, Jean C., 913  
Brent, Robert L., 484  
Brodsky, Jay B., 449  
Brown, Nigel A., 467  
Canter, Jerome W., 853  
Casas-Cordero, Marcos, 949  
Catz, Charlotte, 458  
Chang, R. Jeffrey, 736  
Charles, David, 125  
Chez, Ronald A., 605  
Conrad, John T., 27, 87  
Cordero, José F., 418  
Corson, Stephen L., 334  
Creasy, Robert K., 37  
Crosby, Warren M., 902  
Danforth, David N., 7  
Davis, Margaret R., 832  
Dawood, M. Yusoff, 645, 719, 749  
Delaney, Allen G., 795  
Dewhurst, Sir John, 769  
Duncan, Ian D., 996  
Ekman, Gunvor, 14, 95  
Eschenbach, David A., 186  
Fabro, Sergio, 377, 437, 467  
Faustman-Watts, Elaine, 379  
Fetherston, William C., 929  
Fillkins, Karen, 339  
Forman, A., 56  
Fritz, Marc A., 647  
Gabbe, Steven G., 635  
Gall, Stanley A., 521  
Gardner, Fred M., 213  
Geelhoed, Glenn W., 865  
Giacoia, George P., 458  
Goplerud, Clifford P., 587  
Green, James R., 391  
Hale, Ralph W., 728  
Hamou, Jacques E., 285  
Heinrichs, W. LeRoy, 429  
Hollingsworth, Dorothy Reycroft, 615  
Jones, Howard W., III, 968  
Juchau, Mont R., 379  
Kagan, Risa, 537  
King, Jeffrey C., 437  
Knox, G. Eric, 173  
Kolstad, Per, 938  
Kwart, Arnold M., 890  
Landers, Daniel V., 143, 391  
Laros, Russell K., Jr., 537  
Liggins, Graham C., 47  
Lookingbill, Donald P., 605  
March, Charles M., 302  
Marlow, John, 359  
Marut, Edward L., 749  
McDonough, Paul G., 690  
McGowan, Larry, 843  
Meisels, Alexander, 949  
Meldrum, David R., 762  
Miller, Frank C., 78  
Morin, Carol, 949  
Neuwirth, Robert S., 277  
Oakley, Godfrey P., Jr., 418  
Oliver, Gregory C., 853  
Pelland, Philip C., 321  
Phillips, Michael H., 890  
Pitkin, Roy M., 519, 579  
Plauché, Warren C., 592  
Queenan, John T., 407  
Reame, Nancy, 777  
Reed, Theodore P., III, 313  
Reid, Robert L., 710  
Reindollar, Richard H., 690  
Robertson, Jack R., 347  
Roy, Michel, 949  
Schachter, Julius, 143  
Schwarz, Richard H., 109, 138  
Shepard, Thomas H., 478  
Siegler, Alvin M., 242  
Simon, James A., 810  
Spellacy, William N., 702  
Spence, Michael R., 111  
Speroff, Leon, 647  
Staff, Adolf, 925, 1007

---

*AUTHOR INDEX*

Steiner, Ann L., 37  
Sweet, Richard L., 143, 391  
Syrop, Craig H., 547  
Thurnau, Gary R., 558  
Ueland, Kent, 1, 27, 87  
Uldbjerg, Niels, 14  
Ulmsten, Ulf, 1, 14, 56, 95  
Valle, Rafael F., 253  
Varner, Michael W., 547  
Warsof, Steven L., 822  
Weingold, Allan B., 793, 801  
Wingerup, Lars, 95  
Yaffe, Sumner J., 458  
Yen, S. S. C., 710  
Youngs, David D., 777  
Zaloudek, Charles J., 853

